1,397 compounds, primarily FDA-approved small molecule drugs, are screened for one or more types of activity against various biological targets. The dataset is provided by EvE Bio and is actively generated, with new target data added every other month. Results include measurements such as agonism and antagonism for drug-target interactions.
Use Cases
- Predicting drug-target binding affinity based on quantitative screening results.
- Classifying compounds by their activity type (e.g., agonism, antagonism) against specific targets.
- Screening FDA-approved drug libraries for potential drug repurposing opportunities.
- Training models to identify novel bioactive compounds from the described library.
Strengths
- The compound library contains 1,397 members, providing a substantial screening base.
- Data generation is active, with new targets added on a bimonthly schedule, suggesting ongoing relevance.
- Measurements include multiple activity types (e.g., agonism, antagonism) for each target-drug pair.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count and dataset scale are unknown, which may limit suitability assessment.
- The description metadata is limited; actual data quality requires manual inspection after download.
Provenance
- Source
- EvE Bio
- Collection Method
- Quantitative screening process of a compound library.
- Freshness
- Last updated 2026-04-08 18:25:22; freshness should be verified.